Abstract
Severe asthma affects only a very small part (few percent) of all patients with asthma. In the last few years, specific biological treatment has become readily available for this group of patients in our country.
These biologics already have priority over the use of systemic corticosteroids, and gradually, with the development of recommendations, it is becoming preferred even over high doses of inhaled corticosteroids (after using a combination with additional treatment).1 In the case report of a young patient with severe refractory bronchial asthma, we show that the possibility of choosing among several biologicals and possibly changing the already used choice allows us to set up and conduct targeted treatment according to the patient's individual characteristics.